Systemic exposure bioequivalence study betwn two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate - Trial PACTR201508001240411
Access comprehensive clinical trial information for PACTR201508001240411 through Pure Global AI's free database. This Not Applicable trial is sponsored by Prosonix Limited and is currently Completed. The study focuses on Respiratory; Other.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
other
Sponsor & Location
Prosonix Limited
Timeline & Enrollment
Not Applicable
Jul 30, 2015
Jan 01, 1900
Summary
To determine the bioequivalence of a new formulation of orally inhaled fluticasone propionate and salmeterol xinafoate with the already marketed product, through the measurement of blood level profiles and determination of pharmacokinetic systemic exposure (Cmax and AUC), following charcoal block. The eventual objective is to obtain a marketing authorisation for the new formulation generic product
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR201508001240411
Non-Device Trial

